Nature Communications (Jan 2022)

Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19

  • Avraham Unterman,
  • Tomokazu S. Sumida,
  • Nima Nouri,
  • Xiting Yan,
  • Amy Y. Zhao,
  • Victor Gasque,
  • Jonas C. Schupp,
  • Hiromitsu Asashima,
  • Yunqing Liu,
  • Carlos Cosme,
  • Wenxuan Deng,
  • Ming Chen,
  • Micha Sam Brickman Raredon,
  • Kenneth B. Hoehn,
  • Guilin Wang,
  • Zuoheng Wang,
  • Giuseppe DeIuliis,
  • Neal G. Ravindra,
  • Ningshan Li,
  • Christopher Castaldi,
  • Patrick Wong,
  • John Fournier,
  • Santos Bermejo,
  • Lokesh Sharma,
  • Arnau Casanovas-Massana,
  • Chantal B. F. Vogels,
  • Anne L. Wyllie,
  • Nathan D. Grubaugh,
  • Anthony Melillo,
  • Hailong Meng,
  • Yan Stein,
  • Maksym Minasyan,
  • Subhasis Mohanty,
  • William E. Ruff,
  • Inessa Cohen,
  • Khadir Raddassi,
  • The Yale IMPACT Research Team,
  • Laura E. Niklason,
  • Albert I. Ko,
  • Ruth R. Montgomery,
  • Shelli F. Farhadian,
  • Akiko Iwasaki,
  • Albert C. Shaw,
  • David van Dijk,
  • Hongyu Zhao,
  • Steven H. Kleinstein,
  • David A. Hafler,
  • Naftali Kaminski,
  • Charles S. Dela Cruz

DOI
https://doi.org/10.1038/s41467-021-27716-4
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 23

Abstract

Read online

SARS-CoV-2 infection can lead to progressive pathology in patients with COVID-19, but information for this disease progression is sparse. Here the authors use multi-omics approach to profile the immune responses of patients, assessing immune repertoire and effects of tocilizumab treatments, to find a dyssynchrony between innate and adaptive immunity in progressive COVID-19.